Britain and America have reached a landmark commercial pact that will guarantee no import taxes on British medicine exports going into the US market.
Agreement Details of the Deal
As part of the deal, the UK has agreed to boost spending on pharmaceuticals through the public health system. This pledge secures that tariffs on these crucial goods will be held at zero for a duration of the next three years.
This agreement is in response to earlier warnings to dramatically increase duties on branded pharmaceutical imports, with figures mentioned reaching double the cost.
"This agreement between the United Kingdom strengthens the global environment for new treatments and brings much-needed equity to transatlantic pharmaceutical trade," a statement noted.
Economic Impact
Pharmaceuticals represent one of the the United Kingdom's largest goods shipped to the US, which is easily the biggest market for large British pharmaceutical firms.
Statistics indicate that in the year prior to September, the UK exported pharmaceutical products worth £11.1bn to the US. This figure made up nearly one-fifth of British export trade in that period.
"This deal safeguards jobs, increases capital expenditure and sets the stage for the UK to emerge as a international leader for biotech and pharma," a minister remarked.
Detailed British Pledges
The agreement entails several specific pledges from the United Kingdom:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it deems new medicines to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to increase total public funding on treatments from 0.3 percent of the national economy to 0.6 percent over the next decade.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to control costs will be restricted at fifteen percent. Previously, repayments were more than 20%.
Broader Context
The pact comes amid a ongoing tension between the sector and the ministers over medicine costs and regulatory access.
The disagreement were exacerbated by arguments that American patients were paying a premium for the identical medicines than consumers in the UK and Europe.
Recently, several large drug company projects in the UK have been halted or abandoned, while multi-billion-dollar investments have been pledged toward American operations.
The Science Minister publicly accepted that the NHS needed to increase expenditure on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the last ten years.
